Skip to content
Edward M. Messing, M.D.

Edward M. Messing, M.D.

Urology, Surgery, Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Locations

Urology

601 Elmwood Avenue, 2nd Floor
Rochester, NY 14642

Urology - Sawgrass

158 Sawgrass Drive, 2nd Floor, Suite 230
Rochester, NY 14620

About Me

I chose this field because half of all cancers in men – and almost 20% in women – arise in urologic organs and are treated by urologists. Specializing in urologic oncology is a way of helping many people.

Since I believe that an informed patient makes the wisest decisions regarding treatment,...
I chose this field because half of all cancers in men – and almost 20% in women – arise in urologic organs and are treated by urologists. Specializing in urologic oncology is a way of helping many people.

Since I believe that an informed patient makes the wisest decisions regarding treatment, I spend much time educating my patients about their disease and options for treatment. My approach to patient care is individualized, both in terms of treatments offered and recommended, and in terms of the patient's and his or her family's goals. Treating bladder, kidney, prostate and testicular cancer are among my areas of expertise. I also hold several research grants and patents related to the field of urologic cancer.

Conditions I Treat:

- Bladder cancer
- Kidney cancer
- Prostate cancer
- Testicular cancer
- Adrenal cancer
- Penile cancer
- Scrotal cancer
- Ureteral cancer
- Urethral cancer

Professional Background

Dr. Messing received his MD degree from New York University in 1972, had his surgery training at NYU-Bellevue Hospital in New York 1972-1974, and his Urology Residency at Stanford University 1974-1978. After 2 years on the faculty at Tulane University, he completed a fellowship in Urologic Oncology...
Dr. Messing received his MD degree from New York University in 1972, had his surgery training at NYU-Bellevue Hospital in New York 1972-1974, and his Urology Residency at Stanford University 1974-1978. After 2 years on the faculty at Tulane University, he completed a fellowship in Urologic Oncology at UCLA in 1982. He was on the faculty of the Division of Urology at the University of Wisconsin from 1982-1995, being Director of their Urologic Oncology Program for the last 10 years. He became The W.W. Scott Professor and Chairman of the Department of Urology and maintained that position until he stepped down as Chairman in January, 2018. He remains an active clinician and surgeon and is a Professor of Urology, Oncology, and Pathology at University of Rochester. At the University of Rochester School of Medicine and Dentistry(UR) in September 1995, Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the prostate, bladder, kidney, testicle, penis and other genitourinary organs, carries on extensive research in the basic biology of bladder and prostate cancers, and has been the principal investigator on numerous clinical studies for the detection, prevention and treatment of genitourinary cancers.

Dr. Messing has held numerous leadership positions in institutional, local , regional and national organizations including being a department chairman or over 22 years. interim director of the National Cancer Institute, URMC Cancer Center, being a board member, officer and president of both The Society of Urological Oncology and The North Western Section of the American Urological Association (NSAUA), co chairman of the Genitourinary Group (GU) of the Eastern Cooperative Oncology Group (ECOG) and co-leader of the Renal Cancer Subcommittee of the GU committee of SWOG. (The South West Oncology Group) In September, 2021 he will become the President-elect of the American Urological Association (AUA) to become President May, 2022.

Certified Specialties

Urology - American Board of Urology

Faculty Appointments

Professor - Department of Urology (SMD)

Credentials

Residency & Fellowship

Residency, Urology, Stanford University School of Medicine. 1974 - 1978

Residency, Surgery (General Surgery), Bellevue Hospital Center. 1973 - 1974

Internship, Surgery (General Surgery), Bellevue Hospital Center. 1972 - 1973

Education

MD | New York University School of Medicine. 1972

Awards

SUO Distinguished Service Award. 2020

Ramon Guiteras Award. 2018

Robert S. Davis Teaching Award. 2018

SUO Medal Recipient. 2016

George E. Slotkin Lecturer. 2016

Presidential Citation Award. 2013

2013 Best of Posters Award - AUA - 2013 Annual Meeting. 2013

2012 Best of Posters Award – AUA – 2012 Annual Meeting. 2012

2010 Best of Posters Award - AUA - 2010 Annual Meeting. 2010 - 2010

Davey Award. 2009

American Association of Genitourinary Surgeons (AAGUS). 2007

CaP Cure Award and Best Clincal Research Prostate Cancer. 1999 - 1999

Fellow. 1986 - 1986

Sigma Xi. 1985 - 1985

Junior Faculty Clinical Fellow. 1984 - 1986

First Prize for Clinical Research and the Bill Smart Award for Best Clinical Paper (Interstitial Cystitis). 1977 - 1977

Second Prize for Case Reports (Renal Arteriovenous Fistulas). 1975 - 1975

Alpha Omega Alpha. 1972 - 1972

The Samuel Soifer Memorial Award for Outstanding Work in Urology - 1972. 1972 - 1972

Phil Beta Kappa. 1968 - 1968

Research

Dr. Messing is an internationally renowned expert in all facets of urologic oncology, both as a clinician/surgeon, and as a clinical, translational and basic researcher.

His research contributions have ranged from enhancing our knowledge about the basic molecular biology and genetics of devel...
Dr. Messing is an internationally renowned expert in all facets of urologic oncology, both as a clinician/surgeon, and as a clinical, translational and basic researcher.

His research contributions have ranged from enhancing our knowledge about the basic molecular biology and genetics of development and progression of cancers of the bladder, prostate and kidney, and bringing these studies to fruition for the detection, prevention and treatment of these diseases. He has also designed and conducted landmark phase III clinical trials for each of these cancers and has carried out the first screening trial for bladder cancer in a general population. Important work has included defining the roles of epidermal growth factor (EGF) and its cell surface receptor in urothelial carcinogenesis and progression, investigating polyamine synthesis inhibition as a means to prevent bladder and prostate cancers, in large phase III clinical trials studying DFMO's ability to prevent bladder cancer's recurrence, the timing of androgen deprivation therapy (ADT) in treating regionally advanced completely resected prostate cancer, the effectiveness of adjuvant alpha interferon for completely resected, locally extensive, renal cell carcinoma, and the role of a single intravesical instillation of gemcitabine in preventing recurrence of low grade non-muscle invading bladder cancer (NMIBC). He has also contributed importantly to trials testing various forms of intravesical therapy for high risk, NMIBC, and the value of radiation therapy after prostatectomy for stage pT3 prostate cancer. He has demonstrated the feasibility of screening for bladder cancer (using hematuria reagent strips) and has worked on the development and testing of several molecular markers for the detection of bladder cancer.

Furthermore, his clinical trial work continues as the study coordinator (PI) of a large phase III clinical trial of immediate post TURBT intravesical instillation therapy for prevention of recurrence of low risk bladder cancer.Much of the above mentioned work continues, but currently he is also investigating gender disparities in bladder cancer's incidence and outcome. These efforts have ranged from investigations using large, national data bases, to molecular studies in cells and transgenic animal models. Additionally, he along with his basic science collaborators are investigating the preventative and therapeutic roles of nuclear transcription factors, vitamins and related molecules in prevention and treatment of prostate and bladder cancer.

Patents

Pre- and Intra-Operative Imaging of Bladder Cancer

Issue date: July 28, 2015

Patent #: 9,089,601

Country: United States

Inventors: Dragan J Golijanin, Aimee Johnson Henry, Edward M Messing, Jay Reeder, Ronald W Wood

Intraoperative Imaging of Renal Cortical Tumors and Cysts

Issue date: May 13, 2014

Patent #: 8,725,225

Country: United States

Inventors: Dragan J Golijanin, Edward M Messing

Intraoperative Imaging of Renal Cortical Tumors and Cysts

Issue date: March 08, 2016

Patent #: RE45,916

Country: United States

Inventors: Dragan J Golijanin, Edward M Messing, Ronald W Wood

Publications

Journal Articles

Use of Angiotensin Converting Enzyme Inhibitors is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer.

Kerns SL, Amidon Morlang A, Lee SM, Peterson DR, Marples B, Zhang H, Bylund K, Rosenzweig D, Hall W, De Ruyck K, Rosenstein BS, Stock RG, Gómez-Caamaño A, Vega A, Sosa-Fajardo P, Taboada-Valladares B, Aguado-Barrera ME, Parker C, Veldeman L, Fonteyne V, Bultijnck R, Talbot CJ, Paul Symonds R, Johnson K, Rattay T, Webb A, Lambrecht M, de Ruysscher D, Vanneste B, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Rancati T, Avuzzi B, Valdagni R, Azria D, Farcy Jacquet MP, Chang-Claude J, Seibold P, West C, Janelsins M, Chen Y, Messing E, Morrow G,

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.. 2022 January 22 Epub 01/22/2022.

Increased risk of high-grade prostate cancer among testicular cancer survivors.

Zhang H, Yang H, Bandyopadhyay S, Milano MT, Fung C, Messing EM, Chen Y

PloS one.. 2022 17 (2):e0263573. Epub 02/14/2022.

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.

Correa AF, Jegede OA, Haas NB, Flaherty KT, Pins MR, Adeniran A, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG

European urology.. 2021 March 8 Epub 03/08/2021.

Active Surveillance of Small Renal Masses: A Systematic Review

Ellis EE, Messing EM.

Kidney Cancer. 2021; .

"Risk of Second Cancer among Young Prostate Cancer Survivors" . Radiation Oncology Journal. 2021; in press.

Zhang, H; Yu, A; Baran, A; Messing, E.

Radiation Oncology Journal. 2021; in press. 2021; .

Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.

Gurung PMS, Barnett AR, Wilson JS, Hudson J, Ward DG, Messing EM, Bryan RT

European urology focus.. 2020 July 156 (4):683-697. Epub 02/23/2019.

Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members.

Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM

Urologic oncology.. 2020 May 16 Epub 05/16/2020.

Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis.

Jubber I, Shariat SF, Conroy S, Tan WS, Gordon PC, Lotan Y, Messing EM, Stenzl A, Rhijn BV, Kelly JD, Catto JWF, Cumberbatch MG

European urology.. 2020 May 77 (5):583-598. Epub 11/30/2019.

Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.

Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG

The Journal of urology.. 2020 April 203 (4):684-689. Epub 10/09/2019.

EDITORIAL COMMENT.

Gurung PMS, Messing EM, Joseph JV, Wu G

Urology.. 2020 February 136 :110-111. Epub 1900 01 01.

The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?

Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari D

Clinical genitourinary cancer.. 2020 January 27 Epub 01/27/2020.

Oncologic Outcomes After Partial Cystectomy for Urethiel Cancer

Osinski T, Campbell T, Gantz J, Nelson B, Feng C, Messing EM,.

Canadian Urology Association Journal. 2020; 9(3): S169-S232.

Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA

The Journal of urology.. 2019 November 202 (5):920-926. Epub 10/09/2019.

EDITORIAL COMMENT.

Gurung PMS, Messing EE, Joseph JV

Urology.. 2019 September 131 :118-119. Epub 1900 01 01.

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 August 1037 (23):2062-2071. Epub 06/19/2019.

Pelvic Floor Organ Prolapse After Radical Cystectomy in Patients With Uroepithelial Carcinoma.

Messing E, Doyle PJ, Meyer H, Li D, Lee TG, Lipetskaia L

Female pelvic medicine & reconstructive surgery.. 2019 July 26 Epub 07/26/2019.

ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-?B survival signals.

Huang CP, Chen J, Chen CC, Liu G, Zhang Y, Messing E, Yeh S, Chang C

Journal of experimental & clinical cancer research : CR.. 2019 June 2438 (1):275. Epub 06/24/2019.

Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging.

Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM

European urology oncology.. 2019 May 2 (3):257-264. Epub 01/04/2019.

Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy: A prospective randomized clinical trial.

Berrondo C, Feng C, Kukreja JB, Messing EM, Joseph JV

Urologic oncology.. 2019 March 37 (3):181.e7-181.e14. Epub 12/14/2018.

SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A

World journal of urology.. 2019 January 37 (1):61-83. Epub 01/25/2019.

"Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma"

Kim, HL; Mayerson, E; Lara, PN; Messing, EM; Tangen, C; Shuch, BM; Vaishampayan, U.

Eur Urol Focus. 2019; 5 (6)(doi: 10.1016/j.euf.2019.05.006.): 927-929.

Bladder cancer extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of non-malignant cells.

Wu CH, Silvers CR, Messing EM, Lee YF

The Journal of biological chemistry.. 2018 December 28 Epub 12/28/2018.

The conundrum of recurrent low-grade tumours: to treat or to observe?

Brummelhuis ISG, Witjes JA, Messing EM

Current opinion in urology.. 2018 November 28 (6):557-562. Epub 1900 01 01.

Perioperative Blood Transfusions and Bladder Cancer Outcomes.

Messing EM

Bladder cancer.. 2018 October 294 (4):445-446. Epub 10/29/2018.

Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor ?/IL-1/c-MET signals.

Tao L, Qiu J, Slavin S, Ou Z, Liu Z, Ge J, Guancial EA, Messing EM, Chang C, Yeh S

Cancer letters.. 2018 August 28430 :215-223. Epub 04/22/2018.

Historical and contemporary perspectives on cribriform morphology in prostate cancer.

Truong M, Frye T, Messing E, Miyamoto H

Nature reviews. Urology.. 2018 August 15 (8):475-482. Epub 1900 01 01.

Legends in Urology.

Messing EM

The Canadian journal of urology.. 2018 August 25 (4):9367-9369. Epub 1900 01 01.

Financial Toxicity of Having Bladder Cancer.

Messing EM

Bladder cancer.. 2018 July 304 (3):351-352. Epub 07/30/2018.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM

JAMA.. 2018 May 8319 (18):1880-1888. Epub 1900 01 01.

Psychological Stress and Suicide in Bladder Cancer Patients.

Messing EM

Bladder cancer.. 2018 April 264 (2):245-246. Epub 04/26/2018.

Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy.

Nguyen HG, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean-Gilles J, Yao J, Cooperberg M, Messing E, Klein EA, Carroll PR, Paris PL

The Journal of urology.. 2018 March 199 (3):719-725. Epub 09/20/2017.

Molecular Landscape of Non-Muscle Invasive Bladder Cancer.

Messing EM

Bladder cancer.. 2018 January 204 (1):131-132. Epub 01/20/2018.

Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.

Truong M, Wang B, Gordetsky JB, Nix JW, Frye TP, Messing EM, Thomas JV, Feng C, Rais-Bahrami S

Cancer.. 2018 January 15124 (2):278-285. Epub 10/04/2017.

Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG

The Journal of urology.. 2018 January 199 (1):53-59. Epub 07/18/2017.

A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens.

Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP

The Journal of urology.. 2018 January 199 (1):106-113. Epub 07/18/2017.

Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer.

Silvers CR, Miyamoto H, Messing EM, Netto GJ, Lee YF

Oncotarget.. 2017 October 318 (53):91199-91208. Epub 08/08/2017.

Identification of extracellular vesicle periostin as a urinary biomarker of muscle invasive bladder cancer progression

Lee YF, Silvers C, Liu Y-R, Wu C-H, Miyamoto H, Messing E.

Oncotarget. 2016; 7(17): 23335-23345.

Bladder cancer

Messing, EM.

Paper Alert. 2016; Jan 28;2(1):123-125.

Copper transporter-CTR1 expression and pathological outcomes in platinum-treated muscle-invasive bladder cancer patients

Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES .

Anticancer Res. 2016; 36(2):495-501.

Identification of extracellular vesicle periostin as a urinary biomarker of muscle invasive bladder cancer progression

Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF.

Oncotarget. 2016; Apr 26;7(17):23335-45.

Are we doing

Baack Kukreja JE, Messing EM, Shah JB.

better? The discrepancy between

Paper Alert

Messing EM.

Bladder Cancer. 2016; Apr 27;2(2):283-284.

Baack Kukreja JE, Kiernan M, Schempp B, Siebert A, Hontar A, Dolan J, Noyes K, Dozier A, Ghazi A, Rashid HH, Wu G, Messing.

Quality improvement in cystectomy care with enhanced

Targeting estrogen/estrogen receptor alpha will enhance Bacillus Calmette-Guerin efficacy in bladder cancer

Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S.

Oncotarget. 2016; 15doi: 10.18632/oncotarget.8756.

Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, Mueller E, Streeper N, Uhlman MA, Svatek RS, Messing EM, Lotan Y.

Microscopic haematuria at time of diagnosis is associated

Platinum concentration and pathologic response to cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer

Guancial EA, Kilari D, Xiao G-Q, Abu-Farsakh SH, Baran A, Messing EM, Kim ES.

PLoS One. 2016; May 17;11(5) e0155503.(doi: 0.1371/journal.pone.0155503).

Editorial Comment. Risk factors and microbial distribution of urinary tract infections following radical cystectomy

Messing EM.

Urology. 2016; May 20 pii:S0090-4295(16)30118-2.

Editorial Comment. Risk factors and microbial distribution of urinary tract infections following radical cystectomy

Messing EM .

Urology. 2016; pii: S0090-4295(16)30118-2.

Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH.

Phase Ib placebo-controlled, tissue biomarker trial of

Summary of the 8th annual Bladder cancer think tank: collaborating to move research forward

Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y.

Urol Oncol. 2015; 33(2): 53-64.

Bladder cancer in the elderly patient: challenges and solutions

Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, Mohile SG, Fung C.

Clinical Interventions in Aging. 2015; 10: 939-949.

Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a 'case study'

Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K.

Springer Healthcare/inScience Communications/Diabetes Ther. 2015; 6(3): 357-375.

Effectiveness and safety of extended duration prophylaxis for venous thromboembolism in major urologic oncology surgery

Baack Kukreja JE, Levey HR, Scosyrev E, Kiernan M, Berrondo C, McNamee C, Wu G, Joseph JV, Ghazi A, Rashid H, Dozier A, Messing EM.

Urologic Oncology. 2015; 33(9): 387.e7-387e.16.

Methodology to study the 3D spatial distribution of prostate cancer and their dependence on clinical parameters

Diaz Rojas KE, Montero ML, Yao JL, Messing EM, Fazili AA, Joseph J, Ou Y, Rubens D, Parker KJ, Davatzikos C, Castaneda B.

Journal of Medical Imaging. 2015; 2(3): 037502.

Anti-androgen therapy with Hydroxyflutamide or androgen receptor degradation enhancer ASC-J9® enhances BCG efficacy to better suppress bladder cancer progression

Shang Z, Li Y, Zhang M, Tian J, Han R, Shyr CR, Messing E, Yeh S, Niu Y, Chang C.

Mol Cancer Ther. 2015; 11; pii: molcanther.1055,([Epub ahead of print]).

Methodology to study the 3D spatial distribution of prostate cancer and their dependence on clinical parameters

Rojas KD, Montero ML, Yao JL, Messing EM, Fazili AA, Joseph J, Ou Y, Rubens D, Parker KJ, Davatzikos C, Castaneda B.

J Med Imaging (Bellingham). 2015; 2(3):037502.

Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K.

Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a 'case

Baack Kukreja JE, Levey HR, Scosyrev E, Kiernan M, Berrondo C, McNamee C, Wu G, Joseph JV, Ghazi A, Rashid H, Dozier A, Messing EM.

Effectiveness and safety of extended duration

Editorial Comment

Kukreja JB, Messing EM.

Urology. 2015; 86(5):972-3.

Donsky H, Coyle S, Scosyrev E, Messing EM.

Sex differences in incidence and mortality of bladder

Dunne RF, Sahasrabudhe DM, Messing EM, Jean-Gilles J, Fung C.

A case series of transformation

Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted therapy era

Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ.

Anticancer Research. 2014; (34): 2405-2412.

Scosyrev E, Wu K, Levey HR, Agrawal V, Beckham C, Wu G, Messing.

Overall survival after partial versus radical nephrectomy for a small renal mass: systematic review of observational

Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904

Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H.

European Urology. 2014; 65(2): 372-377.

Kolesar JM, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Kim K, Tangrea JA, Parnes HL, House MG, Gee J, Messing E, Bailey HH.

Soy food frequency questionnaire does not correlate with

Estrogen Receptor ? in Cancer Associated Fibroblasts Suppresses Prostate Cancer Invasion via Modulation of Thrombospondin-2 and Matrix Metalloproteinase 3

Slavin S, Yeh CR, Jun D, Yu S, Miyamoto H, Messing EM, Yeh S.

Carcinogenesis. 2014; 35(6): 1301-9.

Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis (Editorial Comment)

Messing EM.

J Urol. 2014; : 101.

Bladder cancer risk: use of the PLCO and NLST to identify a suitable screening cohort

Krabbe LM, Svatek RS, Shariat SF, Messing E, Lotan Y.

Urol Oncol. 2014; : 65.e19-65.e25.

Micropapillary bladder cancer: current treatment patterns and review of the literature

Willis DK, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TN, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM.

Urol Oncol. 2014; 32(6): 826-32.

Bladder Cancer Exosomes Contain EDIL-3/Del1 and Facilitate Cancer Progression

Beckham C, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen F, Scosyrev E, Messing E, Lee YF.

J of Urology. 2014; 192(3): 690-695.

Impact of Bladder Cancer (BC) on Health-related Quality of Life (HRQL) in 1,476 Older Americans

Fung C, Pandya C, Noyes K, Scosyrev E, Sahasrabudhe DM, Messing EM, Mohile SG.

J Urol. 2014; 192(3): 690-695.

Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo

Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S.

Oncotarget. 2014; 5(17): 7917-35.

E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis

Oncotarget. 2014; 5(23): 12097-110.

Bladder cancer incidence and mortality in patients treated with radiation for uterine cancer

Baack Kukreja J, Scosyrev E, Brasacchio RA, Toy EP, Messing EM, Wu G.

BJUI. 2014; 114: 844-851.

Non-bladder cancer mortality in patients with urothelial cancer of the bladder.

Scosyrev E, Wu G, Golijanin D, Messing E

Urologic oncology.. 2013 July 31 (5):656-63. Epub 05/07/2011.

Screening for bladder cancer: rationale, limitations, whom to target, and perspectives.

Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB

European urology.. 2013 June 63 (6):1049-58. Epub 01/08/2013.

Higher expression of peroxisome proliferator-activated receptor ? or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion.

Yang DR, Lin SJ, Ding XF, Miyamoto H, Messing E, Li LQ, Wang N, Chang C

Urology.. 2013 May 81 (5):1109.e1-6. Epub 03/19/2013.

The management of a clinical t1b renal tumor in the presence of a normal contralateral kidney.

Weight CJ, Miller DC, Campbell SC, Derweesh IH, Lane BR, Messing EM

The Journal of urology.. 2013 April 189 (4):1198-202. Epub 01/18/2013.

Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies.

Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H, Messing E

BJU international.. 2013 March 111 (3 Pt B):E71-7. Epub 09/27/2012.

The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells.

Shyr CR, Chen CC, Hsieh TF, Chang CH, Ma WL, Yeh S, Messing E, Li TH, Li FY, Chang C

Endocrine.. 2013 February 43 (1):191-9. Epub 08/01/2012.

Complications associated with extraperitoneal robot-assisted radical prostatectomy using the standardized Martin classification.

Ghazi A, Scosyrev E, Patel H, Messing EM, Joseph JV

Urology.. 2013 February 81 (2):324-31. Epub 1900 01 01.

The management of a clinical T1b renal tumor in the presence of a normal contralateral kidney: The case for nephron-sparing surgery

Campbell SC, Derweesh IH, Lane BR, Messing EM.

Urology. 2013; 189.

Borch M, Scosyrev E, Baron B, Encarnacion J, Smith EM, Messing E.

A randomized trial of 2% lidocaine gel versus plain lubricating gel for minimizing pain in men undergoing flexible

PSA screening for prostate cancer

Messing, EM.

Doctor's Advice - Monroe County Medical Society. 2013; .

Multispectral photoacoustic imaging of prostate cancer: preliminary ex-vivo results

Dogra VS, Chinni BK, Valluru KS, Joseph JV, Ghazi A, Yao JL, Evans K, Messing EM, Rao NA.

J Clin Imaging Sci. 2013; .

Multispectral photoacoustic imaging of prostate cancer: preliminary ex-vivo results

Dogra VS, Chinni BK, Valluru KS, Joseph JV, Ghazi A, Yao JL, Evans K, Messing EM, Rao NA.

J Clin Imaging Sci. 2013; .

Age and racial differences among PSA-detected (AJCC stage T1cN0M0) prostate cancer in the U.S.: a population-based study of 70,345 men

Zhang H, Messing EM, Travis LB, Hyrien O, Chen R, Milano MT, Chen Y.

Frontiers in Oncology. 2013; Volume 3:312.

1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer

Hsu JW, Yin PN, Wood R, Messing J, Messing E, Lee YF.

Oncotarget. 2013; 4(12): 2397-2406.

Radical versus partial nephrectomy for a small renal mass: does saving nephrons save lives?

Scosyrev E, Messing EM.

Expert Reviews of Anticancer Therapy. 2013; 13(12):1349-51.

N+M0 prostate cancer: local therapy for systemic disease

Messing EM.

Oncology (Williston Park). 2013; 27(7): 661-2, 668.

Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.

Scosyrev E, Wu G, Mohile S, Messing EM

Cancer.. 2012 December 1118 (23):5768-76. Epub 07/30/2012.

Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline.

Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, Messing EM, Miller SD, Peterson AC, Turk TM, Weitzel W,

The Journal of urology.. 2012 December 188 (6 Suppl):2473-81. Epub 10/24/2012.

Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system.

Scosyrev E, Wu G, Golijanin D, Messing E

BJU international.. 2012 November 110 (10):1485-90. Epub 03/27/2012.

Words of wisdom. Re: Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

Messing EM

European urology.. 2012 November 62 (5):935-6. Epub 1900 01 01.

Optical property measurements establish the feasibility of photodynamic therapy as a minimally invasive intervention for tumors of the kidney.

Baran TM, Wilson JD, Mitra S, Yao JL, Messing EM, Waldman DL, Foster TH

Journal of biomedical optics.. 2012 September 17 (9):98002-1. Epub 1900 01 01.

Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression.

Byler TK, Leocadio D, Shapiro O, Bratslavsky G, Stodgell CJ, Wood RW, Messing EM, Reeder JE

BMC urology.. 2012 August 1612 :21. Epub 08/16/2012.

Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.

Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G

Cancer.. 2012 June 15118 (12):3062-70. Epub 10/17/2011.

Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.

Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S

BJU international.. 2012 June 109 (11):1716-26. Epub 01/05/2012.

An unusual cause of an enhancing retroperitoneal mass.

Lloyd GL, Singh MJ, Messing EM

Urology.. 2012 April 79 (4):e61-2. Epub 09/25/2011.

A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.

Messing E, Gee JR, Saltzstein DR, Kim K, Disant'agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H

Cancer prevention research.. 2012 April 5 (4):621-30. Epub 01/31/2012.

A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D.

Ting HJ, Yasmin-Karim S, Yan SJ, Hsu JW, Lin TH, Zeng W, Messing J, Sheu TJ, Bao BY, Li W, Messing E, Lee YF

Cancer research.. 2012 February 1572 (4):958-68. Epub 12/29/2011.

Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder.

Scosyrev E, Messing EM, van Wijngaarden E, Peterson DR, Sahasrabudhe D, Golijanin D, Fisher SG

Cancer.. 2012 January 1118 (1):72-81. Epub 06/30/2011.

The burden of bladder cancer in men and women: analysis of the years of life lost.

Scosyrev E, Golijanin D, Wu G, Messing E

BJU international.. 2012 January 109 (1):57-62. Epub 08/23/2011.

Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens.

Gordetsky J, Scosyrev E, Rashid H, Wu G, Silvers C, Golijanin D, Messing EM, Yao JL

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2012 January 25 (1):140-4. Epub 09/09/2011.

Near infrared fluorescence imaging following intravenous indocyanine green: Initial clinical experience with open partial nephrectomy for renal cortical tumors

Urology. 2012; April 79(4): 958-64.

Robot-assisted laparoscopic partial nephrectomy: review of the first 100 cases from a single institution

Tobis S, Venigalla S, Knopf JK, Scosyrev E, Golijanin D, Erturk E, Joseph JV, Rashid H, Wu GJ.

J Endourology. 2012; July 26(7): 797-802.

Editorial Comment

Knopf J, Messing E.

Urology. 2012; 79(1): 171.

Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview.

Scosyrev E, Messing J, Noyes K, Veazie P, Messing E

Urologic oncology.. 2012 30 (2):126-32. Epub 04/03/2010.

The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing.

Messing EM, Albertsen P, Andriole GL, Carroll PR, Klein EA

Urologic oncology.. 2012 30 (1):117-9. Epub 1900 01 01.

Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).

Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM

BJU international.. 2011 September 108 (5):693-9. Epub 11/24/2010.

Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience.

Gordetsky J, Findeis-Hosey J, Erturk E, Messing EM, Yao JL, Miyamoto H

Canadian Urological Association journal = Journal de l'Association des urologues du Canada.. 2011 August 5 (4):E47-51. Epub 1900 01 01.

Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men.

Purnell JQ, Palesh OG, Heckler CE, Adams MJ, Chin N, Mohile S, Peppone LJ, Atkins JN, Moore DF, Spiegel D, Messing E, Morrow GR

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.. 2011 July 19 (7):899-907. Epub 04/23/2010.

Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study.

Mir C, Shariat SF, Van Der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, Van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR

BJU international.. 2011 July 108 (1):24-30. Epub 11/10/2010.

Lost and now found: retained straight catheter for 20 years.

Bendaña EE, Trivedi D, Marshall J, Messing E

Urology.. 2011 January 77 (1):73-4. Epub 04/09/2010.

Non-bladder cancer mortality in patients with urothelial cancer of the bladder

Scosyrev E, Wu G, Golijanin D, Messing EM.

Urol Oncol. 2011; .

Bilateral testicular epidermoid cysts.

Loberant N, Bhatt S, Messing E, Dogra VS

Journal of clinical imaging science.. 2011 1 :4. Epub 01/01/2011.

Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice.

Scosyrev E, Yao J, Messing E

Urology.. 2010 October 76 (4):908-13; discussion 914. Epub 08/14/2010.

Female bladder cancer: incidence, treatment, and outcome.

Scosyrev E, Trivedi D, Messing E

Current opinion in urology.. 2010 September 20 (5):404-8. Epub 1900 01 01.

Re: Dipstick pseudohematuria: unnecessary consultation and evaluation. P. K. Rao, T. Gao, M. Pohl and J. S. Jones J Urol 2010; 183: 560-565.

Messing EM, Golijanin D, Knopf J, Madeb R

The Journal of urology.. 2010 September 184 (3):1225; author reply 1225-6. Epub 07/31/2010.

Down-regulation of NF-kappaB signals is involved in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.

Bao BY, Ting HJ, Hsu JW, Yasmin-Karim S, Messing E, Lee YF

The Journal of steroid biochemistry and molecular biology.. 2010 May 120 (1):11-21. Epub 03/04/2010.

Controversies surrounding lymph node dissection for prostate cancer.

Palapattu GS, Singer EA, Messing EM

The Urologic clinics of North America.. 2010 February 37 (1):57-65, Table of Contents. Epub 1900 01 01.

Long-term outcome of patients with a negative work-up for asymptomatic microhematuria.

Madeb R, Golijanin D, Knopf J, Davis M, Feng C, Fender A, Stephenson L, Messing EM

Urology.. 2010 January 75 (1):20-5. Epub 11/13/2009.

BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress.

Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y

Urologic oncology.. 2010 28 (3):334-7. Epub 1900 01 01.

BCAN Think Tank session 3: Prevention of bladder cancer.

Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG

Urologic oncology.. 2010 28 (3):338-42. Epub 1900 01 01.

Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer.

Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D

Cancer biomarkers : section A of Disease markers.. 2010 7 (2):101-8. Epub 1900 01 01.

Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria.

Trivedi D, Messing EM

BMC urology.. 2009 September 109 :13. Epub 09/10/2009.

A real-time prostate cancer detection technique using needle insertion force and patient-specific criteria during percutaneous intervention.

Yan K, Podder T, Li L, Joseph J, Rubens DR, Messing EM, Liao L, Yu Y

Medical physics.. 2009 September 36 (9):4184-90. Epub 1900 01 01.

Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease.

Messing EM, Madeb R, Feng C, Stephenson L, Gilchrist KW, Young T, Gee J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2009 May 2027 (15):2443-9. Epub 03/30/2009.

Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment?

Scosyrev E, Yao J, Messing E

Urology.. 2009 April 73 (4):822-7. Epub 02/04/2009.

Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.

Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, Nakada SY, Messing EM

BJU international.. 2009 March 103 (6):736-9. Epub 10/31/2008.

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED

The Journal of urology.. 2009 March 181 (3):956-62. Epub 01/23/2009.

Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice.

Chen M, Hsu I, Wolfe A, Radovick S, Huang K, Yu S, Chang C, Messing EM, Yeh S

Endocrinology.. 2009 January 150 (1):251-9. Epub 08/28/2008.

Treatment of non-muscle invading bladder cancer: Do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors

Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, Knopf J, Lyman G, Messing EM.

Cancer. 2009; 115(12):2660-7.

Sex and racial differences in bladder cancer presentation and mortality in the United States

Scosyrev E, Noyes K, Feng CY, Messing EMM.

CANCER. 2009; Jan 1;115(1): 68-74.

The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794.

Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED,

The Journal of urology.. 2008 December 180 (6):2453-7; discussion 2458. Epub 10/19/2008.

Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?

Singer EA, Golijanin DJ, Messing EM

The Canadian journal of urology.. 2008 December 15 (6):4381-7. Epub 1900 01 01.

Decreased bladder cancer growth in parous mice.

Johnson AM, O'Connell MJ, Messing EM, Reeder JE

Urology.. 2008 September 72 (3):470-3. Epub 06/04/2008.

Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors.

Noyes K, Singer EA, Messing EM

Current opinion in urology.. 2008 September 18 (5):533-9. Epub 1900 01 01.

Androgen receptor is a tumor suppressor and proliferator in prostate cancer.

Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2008 August 26105 (34):12182-7. Epub 08/22/2008.

Quantitative characterization of viscoelastic properties of human prostate correlated with histology.

Zhang M, Nigwekar P, Castaneda B, Hoyt K, Joseph JV, di Sant'Agnese A, Messing EM, Strang JG, Rubens DJ, Parker KJ

Ultrasound in medicine & biology.. 2008 July 34 (7):1033-42. Epub 02/06/2008.

Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1.

Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder JE

BMC urology.. 2008 April 238 :7. Epub 04/23/2008.

Methods for prostate stabilization during transperineal LDR brachytherapy.

Podder T, Sherman J, Rubens D, Messing E, Strang J, Ng WS, Yu Y

Physics in medicine and biology.. 2008 March 2153 (6):1563-79. Epub 02/22/2008.

Why should we increase public awareness of bladder cancer, and how can we do it?

Messing EM

Nature clinical practice. Urology.. 2008 March 5 (3):117. Epub 1900 01 01.

Long-term outcome of dip-stick testing for hematuria

Messing EM, Madeb RM.

World Journal of Urology. 2008; 26(1): 19-24.

Robotic system for prostate brachytherapy.

Yu Y, Podder TK, Zhang YD, Ng WS, Misic V, Sherman J, Fuller D, Rubens DJ, Strang JG, Brasacchio RA, Messing EM

Computer aided surgery : official journal of the International

Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.

Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF

Molecular cancer research : MCR.. 2007 September 5 (9):967-80. Epub 1900 01 01.

Current state of screening for bladder cancer.

Madeb R, Golijanin D, Knopf J, Messing EM

Expert review of anticancer therapy.. 2007 July 7 (7):981-7. Epub 1900 01 01.

Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2007 June 125 (16):2225-9. Epub 1900 01 01.

Promotion of bladder cancer development and progression by androgen receptor signals.

Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C

Journal of the National Cancer Institute.. 2007 April 499 (7):558-68. Epub 1900 01 01.

Mechanical properties of human prostate tissue in the context of surgical needle insertions

Podder TK, Sherman J, L Li, Joseph J, Ruben DR, Messing EM, Huang J, Yu Y.

International Journal of Computer Assisted Radiology and Surgery. 2007; 2007;S106-108.

Microhematuria: Implications of an unexpected finding

Messing, EM.

Consultant. 2007; 47: 356.

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED

JAMA.. 2006 November 15296 (19):2329-35. Epub 1900 01 01.

Long-term outcome of hematuria home screening for bladder cancer in men.

Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, Wegenke JD, Stephenson L, Gee J, Feng C

Cancer.. 2006 November 1107 (9):2173-9. Epub 1900 01 01.

Chemoprevention of bladder cancer.

Golijanin DJ, Kakiashvili D, Madeb RR, Messing EM, Lerner SP

World journal of urology.. 2006 November 24 (5):445-72. Epub 1900 01 01.

Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.

Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G

The Journal of urology.. 2006 August 176 (2):500-4. Epub 1900 01 01.

Vivo motion and force measurement of surgical needle intervention during prostate brachytherapy.

Podder T, Clark D, Sherman J, Fuller D, Messing E, Rubens D, Strang J, Brasacchio R, Liao L, Ng WS, Yu Y

Medical physics.. 2006 August 33 (8):2915-22. Epub 1900 01 01.

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D,

The Lancet. Oncology.. 2006 June 7 (6):472-9. Epub 1900 01 01.

Early detection and measurement of urothelial tumors in mice.

Johnson AM, Conover DL, Huang J, Messing EM, Ning R, O'Connell MJ, Rossi MA, Sun TT, Wood RW, Wu XR, Reeder JE

Urology.. 2006 June 67 (6):1309-14. Epub 1900 01 01.

Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate.

Wood RW, Baggs RB, Schwarz EM, Messing EM

Urology.. 2006 June 67 (6):1324-8. Epub 1900 01 01.

Do prostate cancer patients at risk of pelvic lymph-node metastasis benefit from pelvic radiation?

Palapattu GS, Messing EM

Nature clinical practice. Urology.. 2006 May 3 (5):258-9. Epub 1900 01 01.

Hybrid dosimetry: feasibility of mixing angulated and parallel needles in planning prostate brachytherapy.

Fu L, Liu H, Ng WS, Rubens D, Strang J, Messing E, Yu Y

Medical physics.. 2006 May 33 (5):1192-8. Epub 1900 01 01.

Bladder tumor markers.

Messing EM

The Journal of urology.. 2006 April 175 (4):1195-6. Epub 1900 01 01.

Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.

Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y

JAMA.. 2006 January 18295 (3):299-305. Epub 1900 01 01.

Prostate sonography

Boczko J, Messing EM, Dogra V.

Radiology Clin N Am. 2006; 44(4).

Dynamic planning in single needle brachytherapy systems

V. Misic, L. Fu, T.K. Podder, L. Liao, D.J. Rubens, R. Brasacchio, E.M. Messing, J.G. Strang, W.S. Ng, and Y. Yu.

Int. J. CARS. 2006; 1 (265) 271 – 273.

A method to minimize puncture force and organ deformation

T.K. Podder, L. Liao, J. Sherman, D. Fuller, V. Misic, D.J. Rubens, E.M. Messing, J.G. Strang, W.S. Ng, and Y. Yu.

Int. J. CARS. 2006; 1(265) 277 – 280.

Needle insertion force estimation model using procedure-specific and patient-specific criteria.

Podder TK, Sherman J, Messing EM, Rubens DJ, Fuller D, Strang JG, Brasacchio RA, Yu Y

Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society.. 2006 1 :555-8. Epub 1900 01 01.

Efficacy of prostate stabilizing techniques during brachytherapy procedure.

Sherman J, Podder TK, Misic V, Fu L, Fuller D, Winey B, Messing EM, Rubens DJ, Strang JG, Brasacchio R, Yu Y

Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society.. 2006 1 :563-6. Epub 1900 01 01.

In-vivo measurement of surgical needle intervention parameters: a pilot study.

Podder TK, Sherman J, Fuller D, Messing EM, Rubens DJ, Strang JG, Brasacchio RA, Yu Y

Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society.. 2006 1 :3652-5. Epub 1900 01 01.

Prostate cancer: three-dimensional sonoelastography for in vitro detection.

Taylor LS, Rubens DJ, Porter BC, Wu Z, Baggs RB, di Sant'Agnese PA, Nadasdy G, Pasternack D, Messing EM, Nigwekar P, Parker KJ

Radiology.. 2005 December 237 (3):981-5. Epub 10/26/2005.

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ

Urology.. 2005 December 66 (6 Suppl 1):35-63. Epub 1900 01 01.

Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.

Ni J, Wen X, Yao J, Chang HC, Yin Y, Zhang M, Xie S, Chen M, Simons B, Chang P, di Sant'Agnese A, Messing EM, Yeh S

Cancer research.. 2005 November 165 (21):9807-16. Epub 1900 01 01.

Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States.

Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B, Qian J, Bostwick DG

The Journal of urology.. 2005 October 174 (4 Pt 1):1238-41. Epub 1900 01 01.

Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.

Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C

Molecular carcinogenesis.. 2005 September 44 (1):1-10. Epub 1900 01 01.

Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?

Miyamoto H, Messing EM, Chang C

Nature clinical practice. Oncology.. 2005 May 2 (5):236-7. Epub 1900 01 01.

The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway.

Wang D, Li Z, Messing EM, Wu G

The Journal of biological chemistry.. 2005 April 22280 (16):16393-401. Epub 02/15/2005.

A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis.

Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, Culkin DJ, Diokno A, Hanno P, Landis JR, Madigan R, Messing EM, Nickel JC, Sant GR, Warren J, Wein AJ, Kusek JW, Nyberg LM, Foster HE,

The Journal of urology.. 2005 April 173 (4):1186-91. Epub 1900 01 01.

VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha.

Li Z, Wang D, Messing EM, Wu G

EMBO reports.. 2005 April 6 (4):373-8. Epub 1900 01 01.

Detection of bladder cancer using a point-of-care proteomic assay.

Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y

JAMA.. 2005 February 16293 (7):810-6. Epub 1900 01 01.

Method to reduce force and target movement during surgical needle interventions

Podder TK, Sherman J, Clark DP, Messing EM, Rubens DJ, Strang JG, Liao L, Ng WS, Zhang YD, Yu Y.

European Medical & Biol Engineer. 2005; 11:4315-4320.

Effects of tip geometry of surgical needles: An assessment of force-torque and deflection

Podder TK, Clark DP, Fuller D, Messing EM, Rubens DJ, Strang JG, O'Dell W, Zhang YD, Ng WS, Yu Y.

European Medical & Biol Engineer. 2005; 11:1641-1644.

Prognostic marker for bladder cancer: Bladder Cancer Consensus Panel

Habuchi, T., Marberger, M., Droller, M.J., Hemstreet III, G.P., Grossman, H.B., Schalken, J.A., Schmitz-Drager, B. J., Murphy, W.M., Bono, A.V., Goebell, P., Getzenberg, R.H., Hautmann, S.H., Messing, E., Fradet, Y., Lokeshwar, V.B.

Urology. 2005; 66:64-74.

Bouquet brachytherapy: feasibility and optimization of conically spaced implants.

Fu L, Ng WS, Liu H, O'Dell W, Rubens D, Strang J, Schell MC, Brasacchio R, Liao L, Messing E, Yu Y

Brachytherapy.. 2005 4 (1):59-63. Epub 1900 01 01.

Effects of velocity modulation during surgical needle insertion.

Podder TK, Clark DP, Fuller D, Sherman J, Ng WS, Liao L, Rubens DJ, Strang JG, Messing EM, Zhang YD, Yu Y

Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society.. 2005 6 :5766-70. Epub 1900 01 01.

Androgen deprivation therapy for prostate cancer: current status and future prospects.

Miyamoto H, Messing EM, Chang C

The Prostate.. 2004 December 161 (4):332-53. Epub 1900 01 01.

Uroflow in murine urethritis.

Leung YY, Schwarz EM, Silvers CR, Messing EM, Wood RW

Urology.. 2004 August 64 (2):378-82. Epub 1900 01 01.

Early versus late hormonal therapy for prostate cancer.

Miyamoto H, Messing EM

Current urology reports.. 2004 June 5 (3):188-96. Epub 1900 01 01.

Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator.

Rashid HH, Reeder JE, O'Connell MJ, Zhang CO, Messing EM, Keay SK

BMC urology.. 2004 April 64 :3. Epub 04/06/2004.

A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling.

Wang D, Li Z, Schoen SR, Messing EM, Wu G

Biochemical and biophysical research communications.. 2004 January 9313 (2):320-6. Epub 1900 01 01.

DBCCR1 mediates death in cultured bladder tumor cells.

Wright KO, Messing EM, Reeder JE

Oncogene.. 2004 January 823 (1):82-90. Epub 1900 01 01.

Is there a favorable subset of patients with prostate cancer who develop oligometastases?

Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P

International journal of radiation oncology, biology, physics.. 2004 January 158 (1):3-10. Epub 1900 01 01.

Gender, racial and age differences in bladder cancer incidence and mortality.

Madeb R, Messing EM

Urologic oncology.. 2004 22 (2):86-92. Epub 1900 01 01.

Testicular microlithiasis: a review and its association with testicular cancer.

Rashid HH, Cos LR, Weinberg E, Messing EM

Urologic oncology.. 2004 22 (4):285-9. Epub 1900 01 01.

Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy.

Messing EM, Thompson I

The Urologic clinics of North America.. 2003 November 30 (4):687-702, viii. Epub 1900 01 01.

A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis.

Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM,

The Journal of urology.. 2003 September 170 (3):810-5. Epub 1900 01 01.

Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein.

Na X, Duan HO, Messing EM, Schoen SR, Ryan CK, di Sant'Agnese PA, Golemis EA, Wu G

The EMBO journal.. 2003 August 1522 (16):4249-59. Epub 1900 01 01.

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM

The Journal of urology.. 2003 August 170 (2 Pt 1):588-92. Epub 1900 01 01.

Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line.

Reeder JE, Sowden MP, Messing EM, Klover P, Villa-Moruzzi E, Ludlow JW

Cancer cell international.. 2003 July 233 (1):12. Epub 07/23/2003.

Grade progression and regression in recurrent urothelial cancer.

Borhan A, Reeder JE, O'Connell MJ, Wright KO, Wheeless LL, di Sant'Agnese PA, McNally ML, Messing EM

The Journal of urology.. 2003 June 169 (6):2106-9. Epub 1900 01 01.

Automatic localization of implanted seeds from post-implant CT images.

Liu H, Cheng G, Yu Y, Brasacchio R, Rubens D, Strang J, Liao L, Messing E

Physics in medicine and biology.. 2003 May 748 (9):1191-203. Epub 1900 01 01.

The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.

Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G

The EMBO journal.. 2003 April 1522 (8):1857-67. Epub 1900 01 01.

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2003 April 121 (7):1214-22. Epub 1900 01 01.

Increased expression of the acid sphingomyelinase-like protein ASML3a in bladder tumors.

Wright KO, Messing EM, Reeder JE

The Journal of urology.. 2002 December 168 (6):2645-9. Epub 1900 01 01.

Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.

Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C

Cancer research.. 2002 November 162 (21):6039-44. Epub 1900 01 01.

CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomes.

Gottlieb RH, La TC, Erturk EN, Sotack JL, Voci SL, Holloway RG, Syed L, Mikityansky I, Tirkes AT, Elmarzouky R, Zwemer FL, Joseph JV, Davis D, DiGrazio WJ, Messing EM

Radiology.. 2002 November 225 (2):441-9. Epub 1900 01 01.

Continuous bladder infusion methods for studying voiding function in the ambulatory mouse.

Sessions A, Eichel L, Kassahun M, Messing EM, Schwarz E, Wood RW

Urology.. 2002 October 60 (4):707-13. Epub 1900 01 01.

Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM.

Wang D, Li Z, Messing EM, Wu G

The Journal of biological chemistry.. 2002 September 27277 (39):36216-22. Epub 07/29/2002.

Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor.

Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G

Biochemical and biophysical research communications.. 2002 June 14294 (3):700-9. Epub 1900 01 01.

Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells.

Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S

Proceedings of the National Academy of Sciences of the United States of America.. 2002 May 2899 (11):7408-13. Epub 1900 01 01.

Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.

Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG

The Prostate.. 2002 May 1551 (3):153-65. Epub 1900 01 01.

Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.

Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G

The Journal of biological chemistry.. 2002 February 15277 (7):4656-62. Epub 12/05/2001.

Timing hormonal therapy in prostate cancer.

Sessions AE, Messing EM

The Urologic clinics of North America.. 2002 February 29 (1):223-7, xi. Epub 1900 01 01.

Perspectives on prostate cancer diagnosis and treatment: a roundtable.

Brawer MK, Stamey TA, Fowler J, Droller M, Messing E, Fair WR

Urology.. 2001 August 58 (2):135-40. Epub 1900 01 01.

Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine.

Eichel L, Scheidweiler K, Kost J, Shojaie J, Schwarz E, Messing E, Wood R

Urology.. 2001 July 58 (1):113-8. Epub 1900 01 01.

Continuous bladder infusion methods for studying voiding function in ambulatory mice.

Eichel LS, Sessions AE, Messing EM, Schwarz E, Wood RW

Urology.. 2001 June 57 (6 Suppl 1):115. Epub 1900 01 01.

Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine.

Eichel L, Scheidweiler K, Kost J, Shojaie J, Schwarz E, Messing EM, Wood R

Urology.. 2001 June 57 (6 Suppl 1):115. Epub 1900 01 01.

Human bladder permeability assessment using intravesical fluorescein clearance rate.

Wood R, Pittelli R, Foster D, Mayer R, Messing EM

Urology.. 2001 June 57 (6 Suppl 1):131-2. Epub 1900 01 01.

Real-time US versus CT determination of pubic arch interference for brachytherapy.

Strang JG, Rubens DJ, Brasacchio RA, Yu Y, Messing EM

Radiology.. 2001 May 219 (2):387-93. Epub 1900 01 01.

Localization of androgen receptor expression in human bone marrow.

Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Chang C, Messing EM, Wu JH

The Journal of pathology.. 2001 March 193 (3):361-6. Epub 1900 01 01.

Automated noninvasive measurement of cyclophosphamide-induced changes in murine voiding frequency and volume.

Wood R, Eichel L, Messing EM, Schwarz E

The Journal of urology.. 2001 February 165 (2):653-9. Epub 1900 01 01.

Editorial comment

Messing EM

Urology.. 2000 November 156 (5):791-2. Epub 1900 01 01.

The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study.

deVere White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED

European urology.. 2000 May 37 (5):595-600. Epub 1900 01 01.

Early hormonal therapy in prostate cancer (Editorial)

Messing, EM.

NEJM. 2000; 342:1216.

Molecular mechanisms and pathways in bladder cancer development and progression.

Jung I, Messing E

Cancer control : journal of the Moffitt Cancer Center.. 2000 7 (4):325-34. Epub 1900 01 01.

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D

The New England journal of medicine.. 1999 December 9341 (24):1781-8. Epub 1900 01 01.

Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence.

Jung I, Reeder JE, Cox C, Siddiqui JF, O'Connell MJ, Collins L, Yang Z, Messing EM, Wheeless LL

The Journal of urology.. 1999 December 162 (6):1900-3. Epub 1900 01 01.

Low-dose difluoromethylornithine and polyamine levels in human prostate tissue.

Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplun M, Simsiman R, Wilding G

Journal of the National Cancer Institute.. 1999 August 1891 (16):1416-7. Epub 1900 01 01.

Intraoperative optimized inverse planning for prostate brachytherapy: early experience.

Messing EM, Zhang JB, Rubens DJ, Brasacchio RA, Strang JG, Soni A, Schell MC, Okunieff PG, Yu Y

International journal of radiation oncology, biology, physics.. 1999 July 144 (4):801-8. Epub 1900 01 01.

Effect of angiotensin converting enzyme inhibition on the Doppler waveform in dogs with renal artery stenosis.

Gottlieb RH, Zusman E, Hartley DF, Rubens DJ, Voci SL, Robinette W, Melendez L, Morris TW, Ojha S, Chengazi V, Erturk E, Messing EM

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.. 1999 July 18 (7):481-7. Epub 1900 01 01.

Interstitial cystitis--a light at the end of the tunnel?

Messing EM

The Journal of urology.. 1999 June 161 (6):1797. Epub 1900 01 01.

Automated treatment planning engine for prostate seed implant brachytherapy.

Yu Y, Zhang JB, Brasacchio RA, Okunieff PG, Rubens DJ, Strang JG, Soni A, Messing EM

International journal of radiation oncology, biology, physics.. 1999 February 143 (3):647-52. Epub 1900 01 01.

Mus musculus DBCCR1 mRNA, complete sequence

Ochal LK, Sowden MP, Messing EM, Wheeless LL, Reeder JE.

GenBank Accession. 1999; AF202896.

Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.

Miyamoto H, Yeh S, Lardy H, Messing E, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1998 September 1595 (19):11083-8. Epub 1900 01 01.

Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques.

Pan HJ, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, Chang C

Endocrine.. 1998 August 9 (1):39-43. Epub 1900 01 01.

DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients.

Reeder JE, O'Connell MJ, Yang Z, Morreale JF, Collins L, Frank IN, Messing EM, Cockett AT, Cox C, Robinson RD, Wheeless LL

Urology.. 1998 May 51 (5A Suppl):58-61. Epub 1900 01 01.

Long-term experience with pentosanpolysulfate in interstitial cystitis.

Jepsen JV, Sall M, Rhodes PR, Schmidt D, Messing E, Bruskewitz RC

Urology.. 1998 March 51 (3):381-7. Epub 1900 01 01.

A quantitative assay for assessing allelic proportions by iterative gap ligation.

Stewart J, Kozlowski P, Sowden M, Messing E, Smith HC

Nucleic acids research.. 1998 February 1526 (4):961-6. Epub 1900 01 01.

Prostate and bladder cancer screening.

Goldstein MM, Messing EM

Journal of the American College of Surgeons.. 1998 January 186 (1):63-74. Epub 1900 01 01.

Automated Treatment Planning Engine for Prostate Seed Implant Brachytherapy

Yu Y, Zhang JB, Brasacchio R, Okunieff P, Rubens D, Strang J, Soni A, Messing E.

Int J Rad Onc. 1998; 43:1-7.

Loss of the CDKN2A/p16 locus detected in bladder irrigation specimens by fluorescence in situ hybridization.

Reeder JE, Morreale JF, O'Connell MJ, Stadler WM, Olopade OF, Messing EM, Wheeless LL

The Journal of urology.. 1997 November 158 (5):1717-21. Epub 1900 01 01.

Bladder cancer in renal transplant recipients.

Buzzeo BD, Heisey DM, Messing EM

Urology.. 1997 October 50 (4):525-8. Epub 1900 01 01.

Associations among cystoscopic findings and symptoms and physical examination findings in women enrolled in the Interstitial Cystitis Data Base (ICDB) Study.

Messing E, Pauk D, Schaeffer A, Nieweglowski M, Nyberg LM, Landis JR, Cook YL, Simon LJ

Urology.. 1997 May 49 (5A Suppl):81-5. Epub 1900 01 01.

Pelvic pain following radical retropubic prostatectomy: a prospective study.

Sall M, Madsen FA, Rhodes PR, Jønler M, Messing EM, Bruskewitz RC

Urology.. 1997 April 49 (4):575-9. Epub 1900 01 01.

Chemoprevention of Bladder and Prostate Carcinoma.

Joseph JV, Messing M

Cancer control : journal of the Moffitt Cancer Center.. 1997 March 4 (2):136-141. Epub 1900 01 01.

Bladder Cancer Screening

Kozlowski P, Messing EM.

Family Urology. 1997; : 16-18.

Bladder cancer: natural history, tumor markers, and early detection strategies.

Foresman WH, Messing EM

Seminars in surgical oncology.. 1997 13 (5):299-306. Epub 1900 01 01.

Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.

Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL

The Journal of urology.. 1996 October 156 (4):1280-5. Epub 1900 01 01.

A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy.

Jønler M, Madsen FA, Rhodes PR, Sall M, Messing EM, Bruskewitz RC

Urology.. 1996 September 48 (3):433-40. Epub 1900 01 01.

Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials.

Loprinzi CL, Messing EM, O'Fallon JR, Poon MA, Love RR, Quella SK, Trump DL, Morton RF, Novotny P

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 1996 May 5 (5):371-4. Epub 1900 01 01.

The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with nonpapillary renal cell carcinoma.

Wu SQ, Hafez GR, Xing W, Newton M, Chen XR, Messing E

Cancer.. 1996 March 1577 (6):1154-60. Epub 1900 01 01.

Living related and unrelated donors for kidney transplantation. A 28-year experience.

D'Alessandro AM, Sollinger HW, Knechtle SJ, Kalayoglu M, Kisken WA, Uehling DT, Moon TD, Messing EM, Bruskewitz RC, Pirsch JD

Annals of surgery.. 1995 September 222 (3):353-62; discussion 362-4. Epub 1900 01 01.

Proliferation-independent growth factor modulation of the radiation sensitivity of human prostate cells.

Howard SP, Groch KM, Lindstrom MJ, Messing EM, Gould MN

Radiation research.. 1995 August 143 (2):229-33. Epub 1900 01 01.

Hematuria home screening: repeat testing results.

Messing EM, Young TB, Hunt VB, Newton MA, Bram LL, Vaillancourt A, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD

The Journal of urology.. 1995 July 154 (1):57-61. Epub 1900 01 01.

Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study.

Glazier DB, Bahnson RR, McLeod DG, von Roemeling RW, Messing EM, Ernstoff MS

The Journal of urology.. 1995 July 154 (1):66-8. Epub 1900 01 01.

Penile Merkel cell carcinoma.

Tomic S, Warner TF, Messing E, Wilding G

Urology.. 1995 June 45 (6):1062-5. Epub 1900 01 01.

Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations.

Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD

Urology.. 1995 March 45 (3):387-96; discussion 396-7. Epub 1900 01 01.

Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer.

Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther M, Fisher HA, Messing E

Clinical cancer research : an official journal of the American Association for Cancer Research.. 1995 January 1 (1):57-61. Epub 1900 01 01.

The Cost-Effectiveness of Screening Men for Bladder Cancer Using Chemical Reagent Strips to Detect Microscopic Hematuria

Lawrence WF, Bram LL, Messing EM.

J Urology. 1995; 153: 477.

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, Barton Grossman H

Urologic oncology.. 1995 1 (3):119-26. Epub 1900 01 01.

Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis.

Jønler M, Ritter MA, Brinkmann R, Messing EM, Rhodes PR, Bruskewitz RC

Urology.. 1994 December 44 (6):876-82. Epub 1900 01 01.

Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells.

Kloth MT, Gee RL, Messing EM, Swaminathan S

Carcinogenesis.. 1994 December 15 (12):2781-7. Epub 1900 01 01.

Recovery of epidermal growth factor in voided urine of patients with bladder cancer.

Messing EM, Murphy-Brooks N

Urology.. 1994 October 44 (4):502-6. Epub 1900 01 01.

Sequelae of radical prostatectomy.

Jønler M, Messing EM, Rhodes PR, Bruskewitz RC

British journal of urology. 1994 September 74 (3):352-8. Epub 1900 01 01.

Interstitial cystitis.

Messing EM

The Journal of urology.. 1994 February 151 (2):355-6. Epub 1900 01 01.

Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.

Frederickson SM, Messing EM, Reznikoff CA, Swaminathan S

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 1994 3 (1):25-32. Epub 1900 01 01.

Urological complications in 210 consecutive simultaneous pancreas-kidney transplants with bladder drainage.

Sollinger HW, Messing EM, Eckhoff DE, Pirsch JD, D'Alessandro AM, Kalayoglu M, Knechtle SJ, Hickey D, Belzer FO

Annals of surgery.. 1993 October 218 (4):561-8; discussion 568-70. Epub 1900 01 01.

Redo retroperitoneal lymphadenectomy for germ cell tumor.

Waples MJ, Messing EM

Urology.. 1993 July 42 (1):31-4. Epub 1900 01 01.

A molecular genetic model of human bladder carcinogenesis.

Reznikoff CA, Kao C, Messing EM, Newton M, Swaminathan S

Seminars in cancer biology.. 1993 June 4 (3):143-52. Epub 1900 01 01.

Role of lymphadenectomy in the treatment of renal cell carcinoma.

Phillips E, Messing EM

Urology.. 1993 January 41 (1):9-15. Epub 1900 01 01.

Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors.

Sidransky D, Messing E

The Urologic clinics of North America.. 1992 November 19 (4):629-39. Epub 1900 01 01.

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.

Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1992 August 10 (8):1208-17. Epub 1900 01 01.

Home screening for hematuria: results of a multiclinic study.

Messing EM, Young TB, Hunt VB, Roecker EB, Vaillancourt AM, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD

The Journal of urology.. 1992 August 148 (2 Pt 1):289-92. Epub 1900 01 01.

Age as a predictor of an aggressive clinical course for superficial bladder cancer in men.

Briggs NC, Young TB, Gilchrist KW, Vaillancourt AM, Messing EM

Cancer.. 1992 March 1569 (6):1445-51. Epub 1900 01 01.

A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer.

Loprinzi CL, Messing EM

Journal of cellular biochemistry. Supplement.. 1992 16I :153-5. Epub 1900 01 01.

Epidermal growth factor and its receptor: markers of--and targets for--chemoprevention of bladder cancer.

Messing EM, Reznikoff CA

Journal of cellular biochemistry. Supplement.. 1992 16I :56-62. Epub 1900 01 01.

Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype.

Pink JC, Messing EM, Reznikoff CA, Bryan GT, Swaminathan S

Drug metabolism and disposition : the biological fate of chemicals.. 1992 20 (4):559-65. Epub 1900 01 01.

Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder.

Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ

The Journal of urology.. 1991 December 146 (6):1631-6. Epub 1900 01 01.

Treatment of severe electrical burns of the genitalia and perineum by early excision and grafting.

Edelman GC, Sweet ME, Messing EM, Helgerson RB

Burns : journal of the International Society for Burn Injuries.. 1991 December 17 (6):506-9. Epub 1900 01 01.

Interstitial cystitis.

Messing EM

New York state journal of medicine.. 1991 March 91 (3):91-2. Epub 1900 01 01.

Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study.

Dreicer R, Messing EM, Loehrer PJ, Trump DL

The Journal of urology.. 1990 November 144 (5):1123-6; discussion 1126-7. Epub 1900 01 01.

Hematuria screening for bladder cancer.

Messing EM, Vaillancourt A

Journal of occupational medicine. : official publication of the Industrial Medical Association.. 1990 September 32 (9):838-45. Epub 1900 01 01.

Psychological and mood disturbance associated with the diagnosis and treatment of testis cancer and other malignancies.

Malec JF, Romsaas EP, Messing EM, Cummings KC, Trump DL

Journal of clinical psychology.. 1990 September 46 (5):551-7. Epub 1900 01 01.

Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age.

Messing EM, Young TB, Hunt VB, Wehbie JM, Rust P

Cancer.. 1989 December 164 (11):2361-7. Epub 1900 01 01.

Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.

Goldrath DE, Messing EM

The Journal of urology.. 1989 October 142 (4):1082-4. Epub 1900 01 01.

High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects.

Trump DL, Havlin KH, Messing EM, Cummings KB, Lange PH, Jordan VC

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1989 August 7 (8):1093-8. Epub 1900 01 01.

Epidermal growth factor and bladder cancer: effects of urinary pH

Messing.

EMSurg Forum. 1989; 40: 694-696.

Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion.

Messing EM, Hanson P, Reznikoff CA

Cancer research.. 1988 January 1548 (2):357-61. Epub 1900 01 01.

Case report and review of the literature: uretero-arterial fistula after balloon dilatation and stent placement

Babel SG, McDermott JC, Goldrath DE, Crummy AB, Messing EM.

J Interven Radiol. 1988; 3: 135-138.

Follow-up: recontacting subjects in mutagen exposure monitoring studies.

Busch DB, Bryan GT, Easterling D, Leventhal H, Messing EM, Cummings KB

IRB.. 1988 10 (5):9-11. Epub 1900 01 01.

Epidermal growth factor--interactions with normal and malignant urothelium: in vivo and in situ studies.

Messing EM, Hanson P, Ulrich P, Erturk E

The Journal of urology.. 1987 November 138 (5):1329-35. Epub 1900 01 01.

When cystitis is suspected, what's the next step?

Gillespie L, Messing EM

NAACOG newsletter. 1987 October 14 (10):1, 4-6. Epub 1900 01 01.

Normal and malignant human urothelium: in vitro effects of epidermal growth factor.

Messing EM, Reznikoff CA

Cancer research.. 1987 May 147 (9):2230-5. Epub 1900 01 01.

The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks.

Messing EM, Young TB, Hunt VB, Emoto SE, Wehbie JM

The Journal of urology.. 1987 May 137 (5):919-22. Epub 1900 01 01.

The diagnosis of interstitial cystitis.

Messing EM

Urology.. 1987 April 29 (4 Suppl):4-7. Epub 1900 01 01.

Method for assuring accuracy of bone biopsy using technetium 99 bone scan.

Durzinsky DS, Messing EM, Myerowitz PD, Pellett JR, Wilson MA

Cancer.. 1987 February 1559 (4):723-5. Epub 1900 01 01.

Early stage bladder cancer.

Messing EM

Wisconsin medical journal.. 1987 February 86 (2):14-7. Epub 1900 01 01.

Nonseminomatous germ cell tumor of the testicle: does extensive staging of the primary tumor predict the likelihood of metastatic disease?

Rodriguez PN, Hafez GR, Messing EM

The Journal of urology.. 1986 September 136 (3):604-8. Epub 1900 01 01.

Use of loop double-lumen drainage system to prevent postoperative urinary diversion leaks.

Fisher DT, Messing EM, Bruskewitz RC, Dibbell DG

Urology.. 1986 June 27 (6):553. Epub 1900 01 01.

Lymphocele after retroperitoneal node dissection for testis tumor.

Messing EM, Love RR, Kvols LK

Cancer.. 1986 February 1557 (4):871-4. Epub 1900 01 01.

Recontacting subjects in mutagen exposure monitoring studies.

Busch DB, Bryan GT, Messing EM, Cummings KB

IRB.. 1986 8 (6):1-4. Epub 1900 01 01.

Bilateral rectus femoris pedicle flaps for detrusor augmentation in the prune belly syndrome.

Messing EM, Dibbell DG, Belzer FO

The Journal of urology.. 1985 December 134 (6):1202-5. Epub 1900 01 01.

Spontaneous thrombosis of left spermatic vein: report of 2 cases.

Roach R, Messing E, Starling J

The Journal of urology.. 1985 August 134 (2):369-70. Epub 1900 01 01.

Microscopically controlled surgery in the treatment of carcinoma of the penis.

Mohs FE, Snow SN, Messing EM, Kuglitsch ME

The Journal of urology.. 1985 June 133 (6):961-6. Epub 1900 01 01.

Ornithine decarboxylase activity and polyamine requirements of human bladder cancer

Messing EM, Hanson P, Waters P.

Surg Forum. 1985; 36: 651.

Growth stimulating activity produced by human bladder cancer cells.

Messing EM, Bubbers JE, Dekernion JB, Fahey JL

The Journal of urology.. 1984 December 132 (6):1230-4. Epub 1900 01 01.

Cultures of normal human urothelial cells from ureters of perfused cadaver transplant kidneys.

Schmidt WW, Messing EM, Reznikoff CA

The Journal of urology.. 1984 December 132 (6):1262-4. Epub 1900 01 01.

Murine hybridoma antibodies against human transitional carcinoma-associated antigens.

Messing EM, Bubbers JE, Whitmore KE, deKernion JB, Nestor MS, Fahey JL

The Journal of urology.. 1984 July 132 (1):167-72. Epub 1900 01 01.

Transforming growth factor from human bladder cancer

Messing EM.

Surg Forum. 1984; 35: 662-664.

Growth stimulating activity produced by human bladder cancer cells

Messing EM, Bubbers JE, deKernion JB, Fahey JL.

Surg Forum. 1983; 34: 683-687.

Serum-free medium for the in vitro growth of normal and malignant urinary bladder epithelial cells.

Messing EM, Fahey JL, deKernion JB, Bhuta SM, Bubbers JE

Cancer research.. 1982 June 42 (6):2392-7. Epub 1900 01 01.

Adjuvant therapy for genitourinary cancer.

Messing E, deKernion JB

The Surgical clinics of North America.. 1981 December 61 (6):1331-46. Epub 1900 01 01.

Antibody coating of bacteria persisting in a ureteral stump 10 years after nephrectomy.

Messing E, Tarsin M

The Journal of urology.. 1981 September 126 (3):406-8. Epub 1900 01 01.

Stones in orthotopic, non-obstructing ureteroceles.

Messing EM, Henry SC

The Journal of urology.. 1979 September 122 (3):403-4. Epub 1900 01 01.

Complication of Clorpactin WCS90 therapy for interstitial cystitis.

Messing EM, Freiha FS

Urology.. 1979 April 13 (4):389-92. Epub 1900 01 01.

Emphysematous pyelonephritis

Freiha FS, Messing EM, Gross CM.

J Contin Educ Urol. 1979; : 9-19.

Interstitial cystitis: early diagnosis, pathology, and treatment.

Messing EM, Stamey TA

Urology.. 1978 October 12 (4):381-92. Epub 1900 01 01.

Hypertension and post-traumatic renal arteriovenous fistula: demonstration of unilaterally elevated renin secretion.

Jahnke RW, Messing EM, Spellman MC

The Journal of urology.. 1976 November 116 (5):646-7. Epub 1900 01 01.

Renal arteriovenous fistulas.

Messing E, Kessler R, Kavaney PB

Urology.. 1976 August 8 (2):101-7. Epub 1900 01 01.

Books

Bladder Cancer: Diagnosis and Clinical Management. (2015)

Chapter: HGT1 Bladder Cancer: Diagnosis and Treatment

Authors: Gaya JM, Palou J, Messing EM

Publisher: Wiley-Blackwell 2015

Bladder Cancer (2014)

Chapter: Epidemiology and Natural History

Authors: Messing EM, Scosyrev E

Publisher: Springer 2014

Essentials and Updates in Urologic Oncology, 1st Edition (2011)

Chapter: Bladder Cancer: Epidemiology, risk factors, screening and chemoprevention

Authors: Knopf J, Trivedi D, Messing EM

Publisher: Nova Science Publishers, Inc. 2011

Campbell's Urology (2007)

Chapter: Urothelial Tumors of the Bladder

Authors: Messing EM

Publisher: WB Saunders Co, Philadelphia, PA 2007

Evidence Based Urology (2004)

Chapter: Early Versus Late Hormone Treatment of Metastatic Prostate Cancer

Authors: Madeb R, Golijanin D, Messing EM

Publisher: Castle Hill Barns, Shrewsbury, UK 2004

Campbell's Urology (2002)

Chapter: Urothelial Tumors of the Urinary Tract

Authors: Messing, EM

Publisher: WB Saunders Co, Philadelphia, PA 2002

Prostate Cancer: Biology, Diagnosis and Management (2001)

Chapter: Screening of Prostate Cancer

Authors: Oleyourryk G, Messing EM

Publisher: Oxford University Press, London, UK 2001

Bladder Cancer: Current Diagnosis and Treatment (2001)

Chapter: Diagnosis of Bladder Cancer

Authors: Jung I, Messing EM, Fradet Y

Publisher: Humana Press, Totowa, New Jersey 2001

Invasive Bladder Cancer (2000)

Chapter: Early Diagnosis and Screening

Authors: McNally M, Messing EM

Publisher: Isis Medical Media Limited, Oxford, England 2000

The 5-minute Urology Consult (2000)

Chapter: Cystitis - Hemorrhagic (Infectious, Noninfectious)

Authors: Oleyourryk G, Messing E

Publisher: Lippincott, Williams and Wilkins, Philadelphia, PA 2000

Bladder Cancer: Biology, Diagnosis and Management (1999)

Chapter: Screening of Bladder Cancer

Authors: Goldstein M, Messing EM

Publisher: Oxford University Press, London, UK 1999

Comprehensive Textbook of Genitourinary Oncology (1999)

Chapter: Screening, Early Detection, and Prevention of Bladder Cancer

Authors: Jung I, Messing EM

Publisher: Lippincott Williams & Wilkins, Philadelphia 1999

Advances in Urology (1996)

Chapter: Urothelial cancers of the upper urinary tract

Authors: Buzzeo BD, Messing EM

Publisher: Mosby Year Book, Inc., Chicago, IL 1996

Campbell's Urology (1996)

Chapter: Urothelial Tumors of the Urinary Tract

Authors: Messing, EM, Catalona, WJ

Publisher: WB Saunders Co., Philadelphia, PA 1996

Infertility in the Male (1996)

Chapter: The Effects on Men of Prenatal Exposure to Diethylstilbestrol

Authors: Laitman, CJ, Jonler, M, Messing, EM

Publisher: Mosby, St. Louis, MO 1996

Current Therapy in Hematology - Oncology (1995)

Chapter: Early stage cancers of the prostate, bladder, and kidney

Authors: Bossinger S, Messing EM

Publisher: Mosby, Philadelphia, PA 1995

Comprehensive Textbook of Genitourinary Oncology (1995)

Chapter: Transitional cell carcinomas of the urinary tract: screening, early detection, and prevention

Authors: Jonler M, Messing EM

Publisher: Williams and Wilkins Publications, Baltimore, MD 1995

Prostate Cancer (1994)

Chapter: Optimal management of stage D1 prostate cancer

Authors: Grose GS, Messing EM

Publisher: Wiley-Liss, Inc., New York, NY 1994

Cell Tissue Culture: Laboratory Procedures (1993)

Chapter: Normal human uroepithelial cell culture

Authors: Reznikoff CA, Chen X-R, Messing EM

Publisher: John Wiley & Sons, London, England 1993

Surgical Management of Urologic Disease - An Anatomic Approach (1992)

Chapter: Management of retroperitoneal fibrosis

Authors: Richards III WH, Messing EM.

Publisher: CV Mosby Co., St. Louis, MO 1992

Surgical Management of Urologic Disease - An Anatomic Approach (1992)

Chapter: Ureteral surgery: anatomical overview

Authors: Messing EM, Richards III WH

Publisher: CV Mosby Co., St. Louis, MO 1992

Mastery of Surgery: Urologic Surgery (1992)

Chapter: Urethrectomy

Authors: Messing EM

Publisher: Little, Brown and Co., Boston, MA 1992

Campbell's Urology (1992)

Chapter: Interstitial cystitis and related syndromes

Authors: Messing, EM

Publisher: WB Saunders Co., Philadelphia, PA 1992

Current Therapy in Hematology-Oncology (1992)

Chapter: Genitourinary cancer: prostate, bladder and kidney

Authors: Messing, EM

Publisher: BC Decker Inc., Philadelphia, PA 1992

Current Therapy in Genitourinary Surgery (1992)

Chapter: Testicular seminoma

Authors: Messing EM

Publisher: BC Decker, Inc., Philadelphia, PA 1992

Advances in Urology (1992)

Chapter: The management of stage T1, grade 3 transitional cell carcinoma of the bladder

Authors: Waples MI, Messing EM

Publisher: Mosby-Yearbook, Inc., St. Louis, MO 1992

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.